Labtician Ophthalmics announces commercial launch of Lab TRIACTIV

Author(s):

Martin David Harp

Key Takeaways

Lab TRIACTIV employs advanced cationic liposomal technology to target all three tear film layers, providing sustained hydration and comfort.
The product is preservative-free, contact lens-compatible, and requires fewer daily applications for long-lasting effects.
Key ingredients such as stearylamine and cross-linked sodium hyaluronate optimize tear film stability and support ocular health.
Labtician Ophthalmics aims to set a new benchmark in dry eye care, reinforcing their commitment to advancing visual health.

Lab TRIACTIV is powered by “advanced cationic liposomal technology” for dry eye relief.

(Image Credit: AdobeStock/taffpixture)

Labtician Ophthalmics has announced the commercial launch of Lab TRIACTIV, an artificial tear designed to redefine dry eye relief.

Lab TRIACTIV is powered by “advanced cationic liposomal technology” and targets all 3 layers of the tear film (lipid, aqueous, and mucin) to provide “sustained hydration, enhanced protection, and long-lasting comfort with fewer daily applications.”

The company states that this artificial tear is designed to ensure a longer-lasting effect with fewer applications and that it is preservative-free and contact lens-compatible.

Polydor Strouthos, president of Labtician Ophthalmics commented on the launch in a press release from the company.

"We are incredibly proud to introduce Lab TRIACTIV to the Canadian market, reinforcing our commitment to advancing the Visual Health of Patients with solutions that make a real difference," said Strouthos. "Lab TRIACTIV supports our commitment to redefining industry standards. We are excited to set a new benchmark in dry eye care."

The company noted that the drops ingredients “optimize tear film stability and support ocular health.” These ingredients include stearylamine, cross-linked sodium hyaluronate, trehalose, and phospholipids.